SCHEMBL3044688

SCHEMBL3044688

CC(C)(C)OC(=O)n1ccc2c(O[Si](C)(C)C(C)(C)C)cccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
BRD4 O60885 1/20 0.38
CREBBP Q92793 1/20 0.38
GPR119 Q8TDV5 1/20 0.38
NOTUM Q6P988 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PIM1 P11309 1/20 0.36
MARK3 P27448 1/20 0.36
MAP4K2 Q12851 1/20 0.36
CAMK2B Q13554 1/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
BUB1 O43683 1/20 0.35
HTR6 P50406 3/20 0.35
BCHE P06276 2/20 0.35
LOXL2 Q9Y4K0 1/20 0.35
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29992652 1.00 AKT1 (0.40) AKT1L3MBTL1BRD4CREBBPGPR119
SCHEMBL19645306 0.84 NOTUM (0.41) AKT1L3MBTL1BRD4CREBBPNOTUM
SCHEMBL5958192 0.84 L3MBTL1 (0.51) L3MBTL1BRD4CREBBPMEN1KMT2A
SCHEMBL8211914 0.83 FABP4 (0.46) AKT1L3MBTL1BRD4CREBBPGPR119
SCHEMBL29992759 0.83 FABP4 (0.46) AKT1L3MBTL1BRD4CREBBPGPR119
SCHEMBL3376524 0.82 KDM1A (0.37) MEN1KMT2A
SCHEMBL13003010 0.82 KMT2A (0.39) L3MBTL1MEN1KMT2ABCHE
SCHEMBL24723625 0.81 L3MBTL1 (0.42) AKT1L3MBTL1BRD4CREBBPGPR119
SCHEMBL5025466 0.80 LOXL2 (0.40) KMT2AHTR6BCHELOXL2
SCHEMBL1284244 0.79 L3MBTL1 (0.44) AKT1L3MBTL1BRD4CREBBPNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022232931-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS KARE CHEMICAL TECHNOLOGIES INC. (CA) 2022-11-10 WO disclosed
US-7745641-B2 Nitrogen-containing heterocyclic compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-29 US disclosed
EP-2108642-A1 JAK INHIBITOR Kyowa Hakko Kirin Co., Ltd. (JP) 2009-10-14 EP disclosed
US-20090054407-A1 Nitrogen-containing heterocyclic compound KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1880993-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054407-A1 Nitrogen-containing heterocyclic compound NR4A1, NR5A2, PRMT8 AKT1 2262/4885L3MBTL1 3529/4885BRD4 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.